全文获取类型
收费全文 | 2638865篇 |
免费 | 196326篇 |
国内免费 | 12433篇 |
专业分类
耳鼻咽喉 | 34784篇 |
儿科学 | 85830篇 |
妇产科学 | 72628篇 |
基础医学 | 369278篇 |
口腔科学 | 71005篇 |
临床医学 | 242052篇 |
内科学 | 521263篇 |
皮肤病学 | 63157篇 |
神经病学 | 215754篇 |
特种医学 | 102342篇 |
外国民族医学 | 768篇 |
外科学 | 392062篇 |
综合类 | 62885篇 |
现状与发展 | 19篇 |
一般理论 | 976篇 |
预防医学 | 199311篇 |
眼科学 | 58450篇 |
药学 | 195427篇 |
86篇 | |
中国医学 | 9409篇 |
肿瘤学 | 150138篇 |
出版年
2021年 | 21246篇 |
2019年 | 23090篇 |
2018年 | 31907篇 |
2017年 | 24987篇 |
2016年 | 28454篇 |
2015年 | 32923篇 |
2014年 | 44587篇 |
2013年 | 64275篇 |
2012年 | 85962篇 |
2011年 | 90559篇 |
2010年 | 54953篇 |
2009年 | 52266篇 |
2008年 | 83153篇 |
2007年 | 87749篇 |
2006年 | 89118篇 |
2005年 | 85253篇 |
2004年 | 81221篇 |
2003年 | 78141篇 |
2002年 | 75206篇 |
2001年 | 129661篇 |
2000年 | 132605篇 |
1999年 | 111507篇 |
1998年 | 30784篇 |
1997年 | 27377篇 |
1996年 | 27354篇 |
1995年 | 28133篇 |
1994年 | 25682篇 |
1993年 | 23750篇 |
1992年 | 85528篇 |
1991年 | 81969篇 |
1990年 | 79104篇 |
1989年 | 76336篇 |
1988年 | 69660篇 |
1987年 | 68193篇 |
1986年 | 63691篇 |
1985年 | 60618篇 |
1984年 | 44982篇 |
1983年 | 37911篇 |
1982年 | 22408篇 |
1981年 | 19937篇 |
1979年 | 38919篇 |
1978年 | 27374篇 |
1977年 | 23175篇 |
1976年 | 21426篇 |
1975年 | 22765篇 |
1974年 | 26748篇 |
1973年 | 25339篇 |
1972年 | 23741篇 |
1971年 | 21936篇 |
1970年 | 20166篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
S. Liu A. E. Patanwala J. M. Naylor N. Levy R. Knaggs J. A. Stevens B. Bugeja D. Begley K. E. Khor E. Lau R. Allen S. Adie J. Penm 《Anaesthesia》2023,78(10):1237-1248
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty. 相似文献
2.
3.
4.
Rozhkov V. P. Trifonov M. I. Soroko S. I. 《Neuroscience and behavioral physiology》2022,52(3):383-394
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia... 相似文献
5.
6.
7.
Qiangsheng He Chongfei Huang Xiwen Qin Yuanyuan Yu Di Tang Junjie Huang Zi Chong Kuo Yuyao Ling Deli Mao Bin Xia Wenjing Li Kuiqing Lu Man Yang Yulong He Wenbo Meng Jinqiu Yuan Yihang Pan 《International journal of cancer. Journal international du cancer》2023,153(5):942-949
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes. 相似文献
8.
目的 运用网络药理学方法及分子对接技术探讨黄芪干预腹膜纤维化的可能机制。方法 利用中药系统药理学数据库及分析平台(TCMSP)检索黄芪的主要化学成分及靶点,并补充文献报道相关药理作用的成分作为潜在活性成分。以"peritoneal fibrosis"为关键词分别在OMIM、Genecards获取目前已知的与腹膜纤维化相关的疾病靶点,后取两者的交集靶点;对交集基因通过STRING数据库与Cytoscape 3.7.2软件构建"药物-成分-靶点-疾病"网络及蛋白互作(PPI)网络并筛选核心网络。基于R软件使用Bioconductor生物信息软件对核心靶点进行GO及KEGG富集分析,最终采用AutoDock软件将主要有效成分与核心靶点进行分子对接,得出其结合能力。结果 筛选出20个黄芪活性成分及文献报道有相关药理作用4个, 457药物作用靶点,与674个腹膜纤维化病靶点取交集,得到86个共同靶点。GO功能富集分析提示黄芪拮抗腹膜纤维化主要参与了蛋白激酶B信号转导的调节、细胞对化学的应激反应、炎症反应的调节等通路; KEGG通路富集分析主要涉及调控肿瘤、磷脂酰肌醇-3-羟激酶-蛋白激酶B(PI3K-Akt)、晚期糖基化终末产物/晚期糖基化终末产物受体(AGE-RAGE)、人类巨细胞病毒感染、HIF-1信号通路等;分子对接结果显示关键靶点与活性成分具有较好的结合能力。结论 黄芪治疗腹膜纤维化的分子机制,可能与抑制炎症及氧化应激反应、调节多种信号通路等相关。 相似文献
9.
10.